The Regulatory History of Breast Prostheses 1
Breast prostheses are annually implanted in hundreds of thousands of patients for 2 augmentation of breast size as well as in reconstructive surgeries following injuries or 3 mastectomies, supporting a $1.2 billion industry (5, 6) and providing important improvements 4
in patients' quality of life. (7) Although breast prostheses have been on the market since the 5 1960s, the FDA only gained authority to regulate these devices through the 1976 Medical 6
Device Amendments to the Federal Food, Drug, and Cosmetic Act, which established the basic 7 risk-based regulatory framework for medical devices that remains in place today. In the 1980s, 8 breast prostheses were formally classified as high-risk devices, a distinction with implications 9
for the regulatory oversight of new product submissions as well as the financial commitment 10 from sponsors. For most high-risk medical devices, such as breast prostheses, the FDA requires 11 a premarket approval (PMA) application, which includes sections with information on products' 12 technical aspects, non-clinical laboratory studies, and clinical investigations. Relative to 13 applications for low or moderate-risk products, the PMA application is also costlier for 14 sponsors, who typically need to conduct clinical trials to support product approval. 15
In the case of breast prostheses, a 1989 study revealed that polyurethane foam, a 16 coating on some silicone gel-filled implants, degraded and released 2-toluene diamine, which 17 was known to cause cancer in animals when exposed to a high pH. (8) After the FDA requested 18 additional information about the safety and composition of the foam, the manufacturer 19 removed these implants from the market. Concerns around the safety of these prostheses 20 extended into the 1990s with lawsuits from thousands of women claiming injury from silicone 21
implants, but few studies were published assessing the safety and effectiveness of any 22 marketed product model. The FDA General and Plastic Surgery Devices Panel convened 1 multiple times to determine whether the PMA data was sufficient to establish that the silicone 2 gel-filled breast implants were safe and effective. In 1997, the National Academy of Medicine 3 performed an independent review of all past and ongoing scientific research regarding the 4 safety of silicone breast implants. (8) 5 The maelstrom surrounding breast prostheses represents an ideal context for public 6 discussion and medical and regulatory consensus distilled into comprehensive guidance 7 documents: the setting involves an important clinical need, combined with high public concern 8 about product safety, and a desire from manufacturers and regulators for a consistent and 9 transparent approach to assessing the biochemical, engineering, and clinical aspects of new 10 product submissions. 11
12

FDA Guidance Documents 13
Many guidance documents detail the type of clinical evidence expected in order to 14 attain regulatory approval for new drugs and devices. They represent the FDA's current thinking 15 on a particular product, although, as noted above, they are not legally binding on sponsors or 16 the FDA. The FDA publishes such documents regularly and their full draft and revision history is 17 publicly available. To explore the impact of guidance documents on product research and 18 development, we identified all breast prosthesis approvals over the past 20 years from the 19 FDA's PMA database, (9) alongside all related final regulatory guidance documents published by 20 the CDRH over the same period of time. We also identified all published clinical studies 21 pertaining to breast prostheses. It is difficult to establish a causal relationship between the publication of regulatory 1 guidance and subsequent clinical studies and new product development. We recognize that a 2 limitation is the potential confounding variable that increased attention focused on a particular 3 device area due to clinical or safety concerns may drive an increase in both the number of 4 guidance documents published and innovation in the field. Still, the association between CDRH 5 guidance documents related to breast prostheses and subsequent growth in research and 6 innovation in these devices is compelling. This example illustrates the importance of supporting 7 FDA with sufficient resources to support guidance document drafting, revision, publication, and 8 updating to reflect evolving scientific consensus and the needs of sponsors, regulators, and 9 patients for transparent and consistent standards. Indeed, in recent statements regarding the 10 FDA's budget, Commissioner Scott Gottlieb has highlighted that in the context of "advancing 11 modern drug and biological product manufacturing technologies," additional resources would 12 be used to "lead stakeholders in the development of clear scientific standards, policy and 13 
